Copyright
©The Author(s) 2017.
World J Gastroenterol. Jul 21, 2017; 23(27): 4958-4967
Published online Jul 21, 2017. doi: 10.3748/wjg.v23.i27.4958
Published online Jul 21, 2017. doi: 10.3748/wjg.v23.i27.4958
Covariate | P value |
Demographic variables | |
Gender | NS |
Race | NS |
Montreal Classification | |
Age of onset (A) Montreal | NS |
Location (L) Montreal | NS |
Location (L4) upper GI Montreal | NS |
Behavior (B) Montreal | 0.131 |
Behavior (p) perianal Montreal | 0.091 |
SNP variables | |
ATG16L1 rs10210302 | NS |
ATG16L1 rs2241880 | NS |
FAS Ligand rs763110 | 0.0571 |
FAS Ligand rs763110 (TC + TT grouped) | 0.021 |
IBD5 rs2522057 | NS |
FCGR 3A rs396991 | NS |
TNF gene (-308) rs1800629 | 0.131 |
TNF gene (-308) rs1800629 (AA + GA grouped) | 0.0991 |
TNF gene(-238) rs361525 | NS |
- Citation: Netz U, Carter JV, Eichenberger MR, Dryden GW, Pan J, Rai SN, Galandiuk S. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease. World J Gastroenterol 2017; 23(27): 4958-4967
- URL: https://www.wjgnet.com/1007-9327/full/v23/i27/4958.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i27.4958